Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1515/cclm-2021-0483 http://scihub22266oqcxt.onion/10.1515/cclm-2021-0483 34388325!ä!34388325 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Chem+Lab+Med 2021 ; 59 (12): 1998-2002 Nephropedia Template TP {{tp|p=34388325|t=2021. Alternative detection of SARS-CoV-2 RNA by a new assay based on mass spectrometry |pdf=|usr=}}{{34388325}} gab.com Text Alternative detection of SARS-CoV-2 RNA by a new assay based on mass spectrometry JO: Clin Chem Lab Med http://www.kidney.de/pget.php?&tw=1&pmid=34388325 #FOAvip OBJECTIVES: Accurate detection of SARS-CoV-2 RNA is essential to stopping the spread of SARS-CoV-2. The aim of this study was to evaluate the performance of the recently introduced MassARRAY((R)) SARS-CoV-2 Panel and to compare it to the cobas((R)) SARS-CoV-2 Test. METHODS: The MassARRAY((R)) SARS-CoV-2 Panel consists of five assays targeting different sequences of the SARS-CoV-2 genome. Accuracy was determined using national and international proficiency panels including 27 samples. For clinical evaluation, 101 residual clinical samples were analyzed and results compared. Samples had been tested for SARS-CoV-2 RNA with the cobas((R)) SARS-CoV-2 Test. RESULTS: When accuracy was tested with the MassARRAY((R)) SARS-CoV-2 Panel, 25 of 27 (92.6%) samples revealed correct results. When clinical samples were analyzed with the MassARRAY((R)) SARS-CoV-2 Panel and compared to the cobas((R)) SARS-CoV-2 Test, 100 samples showed concordant results. One sample was found to be inconclusive with the MassARRAY((R)) SARS-CoV-2 Panel. When time-to-results were compared, the new assay showed longer total and hands-on times. CONCLUSIONS: The MassARRAY((R)) SARS-CoV-2 Panel showed a good performance and proved to be suitable for use in the routine diagnostic laboratory. Especially during phases of shortage of reagents and/or disposables, the new test system appears as beneficial alternative to standard assays used for detection of SARS-CoV-2 RNA. Twit Text FOAVip Alternative detection of SARS-CoV-2 RNA by a new assay based on mass spectrometry ????Clin Chem Lab Med http://www.kidney.de/pget.php?&tw=1&pmid=34388325 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34388325 #FOAvip English Wikipedia <ref>{{Cite pmid|34388325}}</ref> Alternative detection of SARS-CoV-2 RNA by a new assay based on mass spectrometry #MMPMID34388325 Stelzl E; Kessler HH; Mustafa HG; Mustafa ME; Santner BI; Seier J; La Torre M; Haushofer AC Clin Chem Lab Med 2021[Nov]; 59 (12): 1998-2002 PMID34388325show ga OBJECTIVES: Accurate detection of SARS-CoV-2 RNA is essential to stopping the spread of SARS-CoV-2. The aim of this study was to evaluate the performance of the recently introduced MassARRAY((R)) SARS-CoV-2 Panel and to compare it to the cobas((R)) SARS-CoV-2 Test. METHODS: The MassARRAY((R)) SARS-CoV-2 Panel consists of five assays targeting different sequences of the SARS-CoV-2 genome. Accuracy was determined using national and international proficiency panels including 27 samples. For clinical evaluation, 101 residual clinical samples were analyzed and results compared. Samples had been tested for SARS-CoV-2 RNA with the cobas((R)) SARS-CoV-2 Test. RESULTS: When accuracy was tested with the MassARRAY((R)) SARS-CoV-2 Panel, 25 of 27 (92.6%) samples revealed correct results. When clinical samples were analyzed with the MassARRAY((R)) SARS-CoV-2 Panel and compared to the cobas((R)) SARS-CoV-2 Test, 100 samples showed concordant results. One sample was found to be inconclusive with the MassARRAY((R)) SARS-CoV-2 Panel. When time-to-results were compared, the new assay showed longer total and hands-on times. CONCLUSIONS: The MassARRAY((R)) SARS-CoV-2 Panel showed a good performance and proved to be suitable for use in the routine diagnostic laboratory. Especially during phases of shortage of reagents and/or disposables, the new test system appears as beneficial alternative to standard assays used for detection of SARS-CoV-2 RNA. |COVID-19 Testing/*methods[MESH] |COVID-19/*diagnosis/virology[MESH] |Humans[MESH] |Mass Spectrometry[MESH] |Nasopharynx/virology[MESH] |RNA, Viral/*analysis/metabolism[MESH] |Reagent Kits, Diagnostic[MESH] |Real-Time Polymerase Chain Reaction[MESH] |Reproducibility of Results[MESH]Alternative detection of SARS-CoV-2 RNA by a new assay based on mass (epmc).pdf DeepDyve Pubget Overpricing